Table 1 Baseline characteristics of all patients (N = 157).
N | % | |
|---|---|---|
Age, years | ||
< 65 | 116 | 73.9 |
≥ 65 | 41 | 26.1 |
Sex | ||
Male | 85 | 54.1 |
Female | 72 | 45.9 |
Primary site | ||
Right colon | 42 | 26.8 |
Left colon | 115 | 73.2 |
Histology | ||
W/D adenocarcinoma* | 10 | 6.4 |
M/D adenocarcinoma* | 118 | 75.2 |
P/D adenocarcinoma* | 29 | 18.5 |
Site of metastasis | ||
Liver | 91 | 58.0 |
Lung | 62 | 39.5 |
Lymph node | 50 | 31.8 |
Peritoneum | 33 | 21.0 |
Others* | 20 | 12.7 |
Sum of metastasis | ||
1 organ metastasis, excluding peritoneum | 65 | 41.4 |
2 or more organ metastasis, excluding peritoneum | 59 | 37.6 |
Any number of organs plus peritoneum | 33 | 21.0 |
RAS mutation | ||
Wild | 74 | 47.1 |
Mutant | 83 | 52.9 |
BRAF mutation | ||
Wild | 142 | 90.4 |
Mutant | 8 | 5.1 |
Unknown | 7 | 4.5 |
Previous systemic treatment lines | ||
2 | 85 | 54.1 |
≥ 3 | 72 | 45.9 |
Time from first diagnosis of metastatic disease to treatment | ||
< 24 months | 74 | 47.1 |
≥ 24 months | 83 | 52.9 |
Previous targeted agents | ||
RAS/RAF wild-type (n = 70) | ||
Prior bevacizumab and cetuximab | 19 | 12.1 |
Prior bevacizumab | 1 | 0.1 |
Prior cetuximab | 32 | 20.4 |
RAS or RAF mutated (n = 87) | ||
Prior bevacizumab | 36 | 22.9 |
Previous chemotherapy | ||
Fluoropyrimidine | ||
Refractory | 157 | 100 |
Intolerant | 0 | 0 |
Oxaliplatin | ||
Refractory | 149 | 96.1 |
Intolerant | 4 | 2.5 |
Irinotecan | ||
Refractory | 156 | 99.4 |
Intolerant | 1 | 0.6 |
